Glucotrack announces repurchase of series a warrants

Rutherford, n.j., july 08, 2025 (globe newswire) -- glucotrack, inc. (nasdaq: gctk), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully repurchased over 90% of its outstanding series a warrants from warrant holders on june 30, 2025.
GCTK Ratings Summary
GCTK Quant Ranking